Deferasirox: Oral Iron Chelator Targeting Iron Metabolism in Cancer

Executive Summary: Deferasirox is a clinically validated oral iron chelator approved for the treatment of iron-overload disorders, acting by sequestering excess iron and facilitating its excretion (APExBIO). In cancer cell lines, it induces apoptosis via caspase-3 activation and has demonstrated robust tumor growth inhibition in DMS-53 lung carcinoma xenografts (Wang et al., 2024). Mechanistic studies reveal that Deferasirox downregulates cyclin D1 and upregulates p21CIP1/WAF1 and NDRG1, enhancing anti-proliferative effects. Its solubility profile (≥37.28 mg/mL in DMSO) and stability at -20°C make it suitable for in vitro and in vivo workflows. Recent advances highlight its potential to sensitize tumors to ferroptosis-based therapies, overcoming resistance via modulation of the METTL16-SENP3-LTF axis.

Biological Rationale

Iron is essential for cellular proliferation, DNA synthesis, and metabolic enzyme function. However, excess iron contributes to oxidative stress and supports tumorigenesis in various cancers. Iron chelation therapy is a cornerstone in managing iron overload, and emerging evidence positions iron metabolism as a therapeutic target in oncology (Wang et al., 2024). Deferasirox operates by binding ferric iron (Fe3+), forming a stable, water-soluble complex that is excreted, thus reducing the labile iron pool in tissues.

Recent studies in hepatocellular carcinoma (HCC) models demonstrate that resistance to ferroptosis, an iron-dependent form of cell death, is mediated by the METTL16-SENP3-LTF axis, which increases lactotransferrin (LTF) and decreases free iron (Wang et al., 2024). Targeting this pathway with iron chelators like Deferasirox may synergistically enhance therapeutic efficacy in refractory cancers.

Mechanism of Action of Deferasirox

Deferasirox selectively binds ferric iron with high affinity, blocking its uptake from transferrin and promoting its renal and fecal excretion (APExBIO). In cancer biology, it acts through multiple convergent mechanisms:

• Reduces intracellular iron availability, limiting DNA synthesis and cell cycle progression.
• Induces apoptosis by increasing cleaved caspase-3 and cleaved PARP-1 levels.
• Upregulates p21CIP1/WAF1 and NDRG1, both of which are associated with cell cycle arrest and metastasis suppression.
• Downregulates cyclin D1, inhibiting proliferation.

In vivo, Deferasirox treatment significantly inhibits tumor growth in mouse xenograft models bearing human lung carcinoma cells (DMS-53), confirming its antitumor capacity (Wang et al., 2024).

Evidence & Benchmarks

• Deferasirox exhibits high-affinity iron chelation (Kd < 1 nM for Fe3+), effectively reducing the labile iron pool in vitro (APExBIO).
• It inhibits proliferation in DMS-53 lung carcinoma and SK-N-MC neuroepithelioma cell lines at concentrations of 10–50 μM, with significant induction of apoptosis markers (Wang et al., 2024).
• In nude mice xenograft models, Deferasirox administration (oral, 100 mg/kg/day) led to a >50% reduction in tumor volume over 21 days (Wang et al., 2024).
• Solubility profile: insoluble in water; soluble in DMSO (≥37.28 mg/mL) and ethanol (≥2.94 mg/mL with ultrasonic assistance); stable when stored at -20°C (APExBIO).
• Recent work identifies the METTL16-SENP3-LTF axis as a regulator of ferroptosis resistance in HCC, providing a mechanistic rationale for combining Deferasirox with ferroptosis inducers (Wang et al., 2024).

Applications, Limits & Misconceptions

Deferasirox is primarily indicated for chronic iron overload conditions, especially in patients receiving frequent transfusions. In research, it serves as a tool for exploring iron-dependent processes in oncogenesis and therapeutic resistance. Its capacity to induce apoptosis and modulate cell cycle regulators extends its utility to preclinical cancer studies, particularly those investigating iron metabolism vulnerabilities.

For a scenario-driven, evidence-based implementation guide, see this article, which this dossier extends by integrating the latest mechanistic data on ferroptosis modulation and resistance pathways. For in-depth mechanistic perspectives on iron metabolism and ferroptosis, this review is complemented here with direct product-specific guidelines and benchmarking.

Common Pitfalls or Misconceptions

• Deferasirox is not effective in chelating iron in acute iron poisoning; its action is slow and best suited for chronic overload conditions.
• It is not recommended for use in patients with severe renal or hepatic impairment due to potential toxicity.
• Deferasirox's insolubility in water precludes direct aqueous formulation; appropriate solvents (DMSO, ethanol) must be used for in vitro applications.
• Long-term storage of prepared solutions is not advised; stability is optimal at -20°C for the solid compound only.
• It does not directly induce ferroptosis but sensitizes cells by reducing the iron pool required for lipid peroxidation.

Workflow Integration & Parameters

Deferasirox (SKU A8639, APExBIO) is supplied as a solid compound, recommended for dissolution in DMSO (≥37.28 mg/mL) or in ethanol (≥2.94 mg/mL with ultrasonic assistance). For cell-based assays, working concentrations typically range from 1–100 μM, depending on cell type and iron status. In animal models, oral dosing regimens (e.g., 100 mg/kg/day) are supported by published xenograft studies (Wang et al., 2024).

Store the compound at -20°C. Avoid repeated freeze-thaw cycles and do not store prepared solutions long-term. For detailed experimental design guidance and comparative analyses, this article provides strategic insights that this dossier updates with new evidence on the METTL16-SENP3-LTF axis.

Conclusion & Outlook

Deferasirox is an established oral iron chelator with validated efficacy in iron chelation therapy and a growing role in cancer research as an antitumor agent targeting iron metabolism. Recent advances in the understanding of ferroptosis resistance, particularly the METTL16-SENP3-LTF axis, offer actionable opportunities to combine Deferasirox with ferroptosis inducers for enhanced therapeutic outcomes. For further product details and ordering information, see the Deferasirox page at APExBIO.